Natco Pharma profit drops 25% as annual revenue slips
The drugmaker reported annual revenue of ₹4,375.9 crore, with fourth-quarter sales falling 36% compared to the same period last year.
— 2 earlier stories on Natco Pharma Ltd. →What's new
- Annual revenue fell 8.5% to ₹4,375.9 crore for the fiscal year ended March 31, 2026.
- Fourth-quarter revenue dropped to ₹816.9 crore from ₹1,287.3 crore a year ago.
- A one-time tax benefit of ₹115 crore cushioned the bottom-line impact.
Why this matters
The 36% revenue contraction in the final quarter indicates a difficult finish to the fiscal year. While the one-time tax gain provided relief, the underlying operational performance shows a clear downward trend. The upcoming earnings call is the next test for management to explain the sudden deceleration.
What we're watching
- Management commentary on the 36% quarterly revenue decline.
- Sustainability of margins without the one-time tax benefit.
- Segmental performance drivers in the upcoming concall.
The full read
Natco Pharma closed fiscal 2026 with a 24.7% drop in net profit to ₹1,418.5 crore. Annual revenue fell 8.5% to ₹4,375.9 crore. The headline figures were softened by a ₹115 crore one-time tax benefit.
But the quarterly data reveals a steeper challenge. Fourth-quarter revenue plummeted to ₹816.9 crore from ₹1,287.3 crore in the year-ago period, marking a 36% contraction. This sharp deceleration in the final quarter is the primary concern. While the company provided audited statements and segmental data, the operational decline is clear. The upcoming concall will be the test for understanding whether this quarterly dip is a temporary hurdle or a shift in the company's growth trajectory.
Earnings are down.
Questions answered
- How did Natco Pharma perform for the full fiscal year?
- The company reported annual consolidated revenue of ₹4,375.9 crore, an 8.5% decline. Net profit fell 24.7% to ₹1,418.5 crore.
- What was the impact of the tax regime change?
- Natco recorded a one-time tax benefit of ₹115 crore. This resulted from the re-measurement of deferred tax assets and MAT credits after the company moved to a new tax regime.
- How severe was the revenue decline in the fourth quarter?
- Consolidated revenue for the quarter fell to ₹816.9 crore, down from ₹1,287.3 crore in the same period last year. This represents a decline of roughly 36%.
- Are these results audited?
- Yes, the fiscal 2026 results are audited and include detailed segmental splits.
Story so far
All notes on NATCOPHARM →- 29 May 2026 · 4:09 PM IST Natco Pharma profit drops 25% as annual revenue slips
- 1d ago Natco's trough is here. The growth math starts next year.
- 1d ago Natco Pharma files audited results for FY26